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Abstract. Expression of the oncogenic form of H-ras
p21 in the mouse myogenic cell line, 23A2, blocks
myogenesis and inhibits expression of the myogenic
regulatory factor gene, MyoDl. Previous studies from
a number of laboratories have demonstrated that the
activation of ras p21 is associated with changes in phos-
pholipid metabolism that directly, or indirectly, lead to
elevated levels of intracellular diacylglycerol and the
subsequent activation of protein kinase C (PKC). To as-
sess the importance of PKC activity to the ras-induced
inhibition of skeletal myogenesis, we examined the
levels of PKC activity associated with the terminal
differentiation of wild-type myoblasts and with the dif-
ferentiation-defective phenotype of 23A2 ras cells. We
demonstrate that there is a 50% reduction in PKC ac-
tivity during normal myogenesis and that PKC activity
T
HE differentiation of skeletal muscle cells involves the
withdrawal of proliferating myoblasts from the cell
cycle, the formation of multinucleate myofibers and
the transcriptional activation of a complete set of muscle-
specific genes (13) . Experiments with cultured myogenic cell
lines have led to the identification of multiple genetic and en-
vironmental factors that influence the establishment and
the proper differentiation of the myogenic lineage. The pro-
tein products of at least five genes, MyoDl, myd, myogenin,
Myf-S, and MRF4, are important to the regulation of myo-
genic differentiation (5, 11, 38, 40, 51) . In addition, depletion
ofserum growth factors from the culture medium is essential
for myocyte fusion and for the coordinate expression of the
contractile protein gene set (reviewed in reference 19), sug-
gesting that growth factor signal transduction pathways con-
trol thesedevelopmental events. In this regard, several labora-
tories have shown that oncogenes such as ras, fos, and src
inhibit skeletal muscle differentiation, presumably by inter-
fering with the proper functioning of intracellular signalling
pathways (see reference 1 for review; 26, 30, 36, 37) .
The signal transduction pathways used by the various in-
ducers and inhibitors of skeletal myogenesis remain un-
known. Recently, our laboratory has shown that the differen-
tiation of the mouse myogenic cell line, 23A2, is blocked
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is required for myoblast fusion, but not for the tran-
scriptional activation of muscle-specific genes . In con-
trast, we found that the differentiation-defective 23A2
ras cells possess two- to threefold more PKC activity
than wild-type myofibers and that reducing the PKC
activity in these cultures does not reverse their non-
myogenic phenotype. On the other hand, if PKC activ-
ity is downregulated in 23A2 cells before the expres-
sion of activated ras p21, myogenesis is not inhibited.
These results suggest that activated ras p21 relies on a
PKC-dependent signal transduction pathway to initiate,
but not to sustain, its negative effects on 23A2 skeletal
myogenesis and underscore the potential importance of
PKC activity to the proper control of skeletal muscle
differentiation.
after transfection of the cells with the activated form of the
human H-ras gene (26) or by exposure of the cells to purified
fibroblast growth factor (bFGF) or transforming growth fac-
torail (TGF-a) (46) . In each case, the inhibition ofmyogene-
sis is associated with the downregulation of the myogenic
regulatory gene, MyoDl (26, 46) . Interestingly, transfection
of 23A2 cells with a constitutive MyoDl cDNA expression
vector restores myogenesis in the ras-inhibited cultures, but
does not reverse the inhibition induced by growth factors (26,
46) . This suggests that ras, bFGF, and TGF-a similarly affect
an intracellular pathway involved in regulating MyoDl gene
expression, but that the growth factors affect an additional
pathway, perhaps involved in the posttranslational modifica-
tion of the MyoDl protein, that is equally critical for the
proper execution of skeletal myogenesis.
The inhibition of MyoDl gene expression by the ras on-
cogene is a convenient nuclear marker for investigating
further the signal transduction pathways mediating the ras-
induced inhibition ofmyogenesis. The humanH-ras gene en-
codes a plasma membrane associated protein, p21, that
resembles eukaryotic G-proteins (reviewed in reference 4).
In a variety of mammalian cell types, expression of a mu-
tated, oncogenic form of ras p21 leads to a constitutive in-
crease in intracellular diacylglycerol (18, 24, 28, 39, 50),
809which serves as an endogenous activator of the serine-
threonine protein kinase C (PKC)' (reviewed in references
34, 35). Activation of PKC also can be achieved experimen-
tally by treating cells with phorbol ester tumor promoters
(reviewed in references 34, 35) and in several systems, phor-
bol esters can duplicate or enhance the physiological effects
of ms oncogene expression (12, 22, 47, 48) . Since MyoDl
is a nuclear phosphoprotein that regulates its own gene ex-
pression (44, 45), it is intriguing to speculate that ras-in-
duced alterations in PKC activity may be important to the
transcriptional regulation of MyoD1 gene expression and
thus important to the control of skeletal myogenesis.
In this study, we have investigated the role of PKC in the
normal differentiation of 23A2 myoblasts and in the non-
myogenic phenotype of23A2 ras cells. We demonstrate that
the differentiation-defective ras cultures exhibit two to three
times more PKC activity than wild-type cells and that
prolonged treatment with the phorbol ester tumor promoter,
12-O-tetradecanoylphorbol 13-acetate (TPA), effectively
downregulates PKC in both cell types. While TPA treatment
advefsely affects myocyte fusion, it does not inhibit the ex-
pression of muscle-specific genes in wild-type 23A2 cellsor
restore myogenesis in the 23A2 ras cultures. Interestingly,
the initial response of 23A2 myoblasts to activated ras p21
relies on PKC activity, since downregulating PKC with TPA
before the expression of the ras oncogene results in a level
of myogenic differentiation that approaches wild-type con-
trols. We conclude from these studies that PKC activity is
essential for ras p21 to initiate its negative effects on skeletal
myogenesis and MyoDl gene expression, butthat once estab-
lished, continued high levels ofPKC activity are not required
for the differentiation-defective ras phenotype to be main-
tained. These results suggest a critical role for PKC in the
establishment of the ras-induced inhibition of 23A2 myogen-
esis and thus in the regulatory mechanisms controlling
MyoDl gene expression in this cell line.
Materials and Methods
Cell Culture
The mouse myogenic cell line, 23A2, (25), was maintained on gelatin-
coated dishes in BME (basal modified Eagle's medium; Gibco Laborato-
ries, Grand Island, NY) supplemented with 15% fetal bovine serum and
100U/ml penicillin and 100 Ag/ml streptomycin (P/S). Terminal differentia-
tion was induced in subconfluent 23A2 cultures by replacing the growth
medium with a defined medium, ITS (52), for 2 d. For experiments in which
fusion was scored, enhanced morphological differentiation of the cultures
was obtained by treating subconfluent 23A2 monolayers with F12 medium
(Gibco Laboratories) supplemented with 15% horse serum, 100 mM
CaC12, and P/S for 4 d. The 23A2 pT249a2 cell line is a subclone of 23A2
pT249 (26) and is transfected stably with the oncogenic form of the human
H-ras gene. For all experiments, the culture conditions for the 23A2
pT249a2 cells were the same as those described for the parental 23A2 myo-
blast cell line.
Transfections
23A2 myoblasts weretransfected with calciumphosphate precipitates as de-
scribed previously (27, 14) with the following modifications. For stable
transfections, 5 x 105 cells were seeded per 100-mm dish. On the next day
1. Abbreviations used in thispaper: CAT, chloramphenicol acetyltransferase ;
4a-PMA, 4a-phorbol 12-myristate 13-acetate; MCK, muscle creatine ki-
nase; PKC, proteinkinase C ; Thl, troponinI ; TPA, 12-O-tetradecanoylphor-
bol 13-acetate.
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precipitates containing 30 ng of pKOneo (43) and 300 ng ofeither p3B (42)
or pT24 (42) were added to each dish. After 5-6 h, the precipitates were
removed and replaced with fresh growth medium. 24 h later, each plate of
cells was split 1:10 into growth medium supplemented with an active con-
centration of 400 ug/mI of G418 (geneticin; Gibco Laboratories). After
colonies had formed (N15 d), cultures were treatedwithF12differentiation-
inducing medium, fixed, and stained with Giemsa (EM Diagnostic Sys-
tems, Inc., Gibbstown, NJ) (25) . Percent differentiationwas determined by
microscopic examination and represents the number of colonies displaying
discrete myofibers over the total number of colonies examined. For ex-
perimental groups treated with TPA or the nonfunctional TPA analogue4a-
phorbol 12-myristate 13-acetate (4a-PMA) (L. C. Services Corporation,
Woburn, MA), a 2 mg/ml solution in ethanol (100%) was used to supple-
ment the growth or differentiation medium. For transient transfections,
1 x 105 23A2 myoblasts or 23A2 pT249a2 cells were seeded per 100-mm
dish. After 2 d, precipitates containing 5 Ag of5x THE CAT (2) and 5 kg
ofthe reference plasmid, RSV1acZ (23), were added to each dish. 4 h later,
the cells were shocked osmotically for 2 min with 5 ml of 20% glycerol in
BME and then immediately refed fresh growth medium. After 48 h, protein
extracts were prepared as described previously (14) and stored at -20°C
until evaluated for CAT activity (see below). 23A2 myofiber transfections
were performed exactly as described above with the exception that the cells
were seeded at 4 x 105 cells per 100-mm dish and were treated with ITS
differentiation-inducing medium after the glycerol shock.
CATAssays
Cell extracts were assayed for chloramphenicol acetyltransferase (CAT) ac-
tivity as described previously (14). The activities reportedrepresenttheper-
cent conversion of chloramphenicol to the acetylated form averaged from
two independent transfection experiments. Each assay was maintained
withinthe linearrangeof CAT activity. Tocontrol forthe efficiency oftrans-
fection, the cell extracts were normalized with respect to the activity ofthe
cotransfected 0-galactosidase gene (RSV1acZ) asdescribed in Nielson et al.
(33).
Creatine KinaseAssays
Cell extracts from ITS-treated 23A2 and 23A2 ras cells were assayed for
the muscle isoform of creatine kinase (MCK) as described previously (26) .
Each value for NICK activity represents the mean of two independent ex-
periments and has been adjusted for the background level of MCK activity
measured in control 23A2 myoblast extracts.
Immunocytochemistry
Cultures were fixed and immunochemically stained as described previously
(27) using Vectastain ABC reagents (Vector Labs, Burlingame, CA) and
MF-20, a mouse monoclonal antibody thatis specific for the skeletal myosin
heavy chain proteins (3). The stained cultures were examined microscopi-
cally under bright light conditions at 25x and the percentage of cells ex-
pressing myosin heavy chain protein was determined by dividing the num-
ber of nuclei in myosin-positive cells by the total number ofnuclei counted
in a given field. Myofiber formation is expressed as the percentage of total
nuclei contained within myosin-positive cells having two or more nuclei.
To arrive at these determinations, two independent experiments were per-
formed in which at least five randomly chosen microscope fields, each con-
taining approximately 100 nuclei, were examined for each experimental
group.
Northern Blot Hybridizations
Total RNA was isolated from cultures using the method of Chomczynski
and Sacchi (7). 15 kg of RNA from each sample were electrophoresed
through a 1% formaldehyde-agarose gel and transferred to nitrocellulose
(Schleicher & Schuell, Inc., Keene, NH) as described previously (46).
Filters were prehybridized at 65°C in 6x SSC (20x SSC: 3 M NaCl, 300
mM Na-citrate, pH 7.0), 20 mM Tris, pH 7.5, and IOx Denhardt's solution
for 2-4 h and in 6x SSC, 20 mM Tris, pH 7.5, 2 mM EDTA and 0.5% SDS
containing 100 mg/ml heat-denatured salmon sperm DNA for an additional
2 h. Radioactive probes, including the 2 .9-kb Sstl ras-specific fragment
from pT24 (15), the 1.2-kb EcoRI troponin I-specific fragment from
cM113aR (27) and the 1.8-kb EcoRl MyoDl-specific fragment from
pEMClls (11), were labeled, using a-32P dCTP (sp act 3,000 Ci/mmol;
Amersham Corp., Arlington Heights, IL) and the oligolabeling procedure
810of Feinberg and Vogelstein (16, 17) . Denatured probes (sp act > 1 x 108
cpm/1g) were added directly to the filters in the second prehybridization
solution and incubated at 65°C for 12-18 h with gentle agitation. The filters
were washed in 0.1 x SSC, 2 mM EDTA and 0.1% SDS at room temperature
for 10 min and at 68°C for 2 h with one change ofbuffer. To visualize the
hybridization signals, the filters were exposed to XAR film (Kodak) at
-80°C with an intensifying screen for 12-24 h .
Extraction ofPKCfrom Cells
For the determination of PKC activity in proliferating 23A2 or 23A2 ras
cells, cultures were seeded in growth medium at 4 x 105 cells per 75-cm2
flask and extracts wereprepared after48 h. To obtain myofiber extracts, cul-
tures were seeded in growth medium at 4 x 105 cells per 75-cm2 flask on
day 0, treated with ITS medium on day 2, and extracts isolated on day 4.
Cultures were washed twice with cold (4°C) PBS (145 mM NaCl, 8.7 mM
Na2HP04, 1.3 mM NaH2PO4, pH 7.5), once with cold 7.5% sucrose in
20 mM Tris, pH 7.4, and permeabilized for 90 s with 1 ml of cold lysis
buffer (20 mM Tris, pH 7.4, 5 mM EGTA, containing 5001g/ml digitonin,
101g/ml of leupeptin, 101g/ml aprotinin, and 101g/nrI pepstatin). Cyto-
solic extracts were collected after this permeabilization treatment. The re-
maining cell debris was scraped in 1 ml of cold lysis buffer containing 2%
CHAPS; disrupted by sonication for 5 s using a Sonifier Ultrasonicator
(Heat Systems, Ultrasonics, Inc., Plainview, NY) and clearedby centrifuga-
tion in a rotor (SS34 rotor; Sorvall Instruments, Div., Newton, CT) at
20,000 rpm for 20 min at 4°C. The supernatants isolated by this procedure
represent membrane extracts.
PKCAssays
PKC activity was measured by the in vitro kinase assay as described previ-
ously (49). Briefly, 5-10 1g of cytosolic or membrane extracts were in-
cubated for 10 min at 37°C in 20 mM Tris, pH 7.4, 10 MM M9C12, 0.5
mM CaC12, 10 mM p-nitrophenyl phosphate, 20 1M ~1P ATP (sp act
0.2-1.0 Ci/mmol) containing 80 1g/ml phosphatidylserine and 240 1g/ml
lysine-richhistone Hl (Sigma Chemical Co., St. Louis, MO). To assess the
contribution ofkinases other than PKC tothe activityof each extract, dupli-
cate samples were assayed in the presence of 1 mM EGTA and 15 mg/ml
CHAPS, in the absence of CaC12 and phosphatidylserine. All reactions
were terminated by spotting 50-11 aliquots on phosphocellulose filter paper
(P81; Whatman Inc., Clifton, NJ). The filters were washed three times in
water, dried, and the amount of 32p incorporated into histone determined
by scintillation counting. PKC activity is calculated as picomoles of 32p in-
corporated into histone per minute per milligram protein extract. Although
cytosol and membrane extracts were assayed separately, the PKC activities
reported represent the total activity (cytosol plus membrane) measured for
each experimental group.
Immunoblots
Equal volumes of cytosol and membrane extracts were pooled from each
experimental group and assays were performed on 66 mg of total cell ho-
mogenate. Samples were denatured in 5 mg/ml SDS containing 1% 2-mer-
captoethanol and electrophoresed through a discontinuous 10% denaturing
polyacrylamide gel by the method of Laemmli (29). The proteins were
transferred electrophoretically to nitrocellulose overnightat 4°C. The filters
were blocked with 5 % Carnation Instant Milk in TNS (15 mM Tris, pH 7.4,
145 mM NaCI) for 10-20 min at room temperature and then incubated with
anti-rat brain PKC egg yolk antibodies (49) in incubation buffer (TNS con-
taining 1 % BSA, 0.5% sodium azide, and 5 % Carnation Instant Milk) for
a minimum of 2 h. The filters were washed for a total of 25 min in five
changes of TNS containing 1% 'Itveen 20, reblocked with 5 % milk in TNS
for 5 min, and then reacted with rabbit anti-chicken egg yolk antibodies in
incubationbuffer forat least 2 h. The filters were washed againin 1% Tween
20 in TNS as described above and incubated with 201Ci of 1251-protein A
(sp act 10-100 mCi/mg; New England Nuclear, Boston, MA) per 100 ml
of incubation buffer for a minimum of 2 h. After a final set of washes with
1% Tween 20 in TNS the filters were exposed to XAR film (Kodak) at
-80°C with an intensifying screen.
Immunoprecipitations
Cells were plated in normal growth medium at a density of 2 x 105 cells
per 60-mm dish and on the nextday, fed fresh medium with or without 500
nM TPA. 24 h later, the cultures were fed methionine-free DMEM (Dul-
becco's Modified Eagle's Medium) supplemented with 20 mM Hepes,
5% fetal bovine serum, P/S, and 500 nM TPA (where appropriate) for 2 h,
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and methionine-free DMEM containing 200 1Ci/ml of Trans35S (sp act
>1,000 Ci/mmol; ICN Biochemicals, Irvine, CA) for 6 h. The cells were
rinsed with PBS, scraped in 1 ml of PBSTDS (10 mM sodium phosphat° 
pH 7.25, 0.9 % NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1 A
SDS, 0.2% sodium azide) and lysed by passing the suspension through a
21-gauge needle five times. The lysate was cleared by centrifugation at
100,000 rpm in a rotor (TLA 100.3 ; Beckman Instruments, Inc., Palo Alto,
CA) for 5 min at 4°C. 4 x W cpm of each extract were incubated over-
night at 4°C with or without the pan-reactive anti-ras p21 monoclonal anti-
body, Y13-259 (prepared as described below), and then incubated with
20 11 ofcoated protein A-Sepharose (prepared as described below) at 4°C
for 4-6 h. After five washes with 1 ml of PBSTDS, the precipitates were
resolved on a 12.5% denaturing polyacrylamide gel (29). Molecular weight
standards were visualized by staining with Coomassie brilliant blue and
then the gel was treated with Enlhance (DuPont Corp., Wilmington, DE),
dried and exposed to XAR film (Kodak) at room temperature. To quantitate
rasp21 ineach sample, portions ofthe gel correspondingtothe signals were
excised, dissolved in a 95:5 (vol/vol) mixture of 30% H202 and NH40H,
and counted in a scintillation counter. Background counts from lanes pre-
cipitated without the Y13-259 antibody were subtracted from each sample
and the remaining counts expressed as cpm/mg protein. Protein concentra-
tion was determined in parallel extracts not exposed to radioactivity. The
values reported in Fig. 7 B represent the average of three independent
experiments.
Precoated protein A-Sepharose was prepared by incubating 1 1g ofpro-
tein A-Sepharose (Sigma Chemical Co.) overnight at 4°C with 21g ofcell
homogenate and 0.7 1g of rabbit anti-rat antibody (Sigma Chemical Co.)
in the presence ofleupeptin (1 1g/ml), antipain (21g/ml), benzamidine (10
1g/ml), 1% aprotinin, and 1 mM PSMR The coated Sepharose was rinsed
five times with PBSTDS and resuspended as a 1:1 slurry in PBSTDS.
To obtainthe Y13-259antibody, 259 rathybridomacells (20) were grown
in DMEM supplemented with 10% fetal bovine serum, 20 mM Hepes, and
P/S. The medium was collected after 3-5 d, centrifugedto removethe cells,
and the antibody precipitated with 50 % ammonium sulfate. The precipitate
was resuspended in PBS and dialyzed against PBS before use.
Results
Differentiation-defective rasMyoblastsExhibit
ElevatedLevels ofProtein Kinase CActivity
Expression of the human H-ras oncogene in the mouse myo-
genic cell line, 23A2, inhibits both the morphological and
the biochemical differentiation of the cells (26) . This block
in differentiation appears to be associated directly with the
downregulation of the myogenic regulatory factor gene,
MyoDl, since introducing a constitutively expressed MyoDl
cDNA into 23A2 ms cells restores myogenic competence in
these cultures (26) . To dissect further the biochemical path-
ways through which ras p21 inhibits myogenesis and MyoDl
gene expression, we examined differentiation-defective ras
myoblasts for altered levels of the calcium- and phospho-
lipid-dependent protein kinase, PKC. Cell extracts were pre-
pared from proliferating 23A2 myoblasts, from proliferating
23A2 cells stably transfected with the human H-ras onco-
gene (23A2 pT249a2), and from cultures of 23A2 and 23A2
pT249a2 cells that had been induced to differentiate by treat-
ment with the serum-free medium, ITS (52) . Although wild-
type 23A2 myoblasts exhibit extensive differentiation when
induced with ITS, 23A2 pI249a2 cells do not fuse and do not
express skeletal muscle-specific genes (26) . Examination of
PKC activity in these cells revealed that proliferating 23A2
ras cells contained -40% more PKC activity than extracts
from wild-type 23A2 myoblasts (Fig. 1) . After treatment
with ITS, PKC activity decreased by 50% in the fully dif-
ferentiated 23A2 myofiber cultures and by 25% in the dif-
ferentiation-defective 23A2 ras cells, with the ras cultures re-
taining a twofold higher level ofPKC activity than wild-typeFigure 1. PKC activity in wild-type 23A2 cells (23A2) and in differ-
entiation-defective 23A2 pT249a2 cells (2342-ras) . Extracts from
proliferating (B) and differentiation-induced (F) cultures were as-
sayed for the ability to phosphorylate histone Hl in a calcium-
and phospholipid-dependent manner as described in Materials and
Methods. PKC activity is expressed as picomoles of 32P incorpo-
rated into histone per minute per milligram of protein . Each value
represents the average of six independent determinations of PKC
activity. The high and low values for each group of determinations
are indicated by the range bars .
myofibers . This higher level was approximately equal to that
of proliferating 2342 myoblasts, suggesting that PKC activ-
ity may be involved in maintaining the undifferentiated state
of the ras cultures . The increased level ofPKC activity asso-
ciated with ras expression is not unique to the 2342 pT249a2
Figure 2 . TRE-CAT activity in 2342 and 2342-ras cells . Cells were
transfected transiently with 5 jig of the 5XTRE-CAT reporter plas-
mid and 5 wg of the RSV1acZ reference plasmid as described in
Materials and Methods. Extracts were prepared from proliferating
(B) and differentiation-induced (F) cells, normalized for /3-ga-
lactosidase activity, and then assayed forCAT activity as described
in Materials and Methods . CAT activity is reported as the percent
conversion of chloramphenicol to its acetylated form . TheCAT as-
say shown is one of two independent experiments whose results
were averaged to obtain the percent conversions presented .
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cell line since in vitro kinase assays performed on two addi-
tional 23A2 ras clones, 2342 pT248 and 23A2 pT2410 (26),
produced similar results (data not shown) .
To confirm that the levels of PKC activity measured in
vitro reflect the activity of PKC in vivo, 23A2 and 23A2
pT249a2 cells were assayed for their ability to express a
chloramphenicol acetyltransferase (CAT) reporter gene con-
trolled by a PKC responsive DNA element (TRE) (2) . 23A2
and23A2 pT249a2 cells were transfected transiently with the
TRE-CAT reporter gene and proliferating and differentiation-
induced cultures monitored for CAT activity (see Materials
and Methods for details) . As shown in Fig . 2, treatment of
23A2 myoblasts with ITS resulted in a 40% decrease in TRE-
CAT activity, which paralleled the decrease in the in vitro
kinase activity measured in these same cultures (Fig . 1) . As
expected, 23A2 pT249a2 cells also exhibited a modest de-
crease inTRE-CAT activity when treated with ITS . However,
CAT expression remained approximately twofold higher in
the differentiation-defective ras cultures than in the differen-
tiation-competent 23A2 myofiber cultures . These studies
agree with the previous in vitro kinase assay results (Fig . 1)
and suggest that the increased levels of PKC activity found
in 23A2 ras cells may be important to their differentiation-
defective phenotype.
PKC IsDownregulated in 2342 and 2342 ras Cells
After Treatment with TPA
The elevated level of PKC activity associated with ras on-
cogene expression in 2342 cells could be due to an increased
rate of PKC protein synthesis, the expression of additional
PKC isozymes, or to a decrease in the efficiency ofPKC pro-
tein degradation . To begin investigating these possibilities,
in vitro kinase assays and Western blot analyses were per-
formed to measure PKC activity and PKC protein levels in
2342 and 2342 pT249a2 cultures that had been treated with
increasing concentrations of the phorbol ester tumor pro-
moter, TPA . As reported previously, exposure ofa variety of
cell types to TPA causes a transient increase in PKC activity
which is followed by the downregulation of the activated en-
zyme via a host cell proteolytic pathway (reviewed in refer-
ences 34, 35) . Thus, if the transfection of 2342 cells with
activated ras p2l elevates intracellular PKC activity by in-
hibiting the pathway ofPKC degradation, or by stimulating
production ofPKC isozymes that are resistant to the effects
of phorbol esters (9), the PKC pool in 2342 cells should be
downregulated by TPA more efficiently than the PKC pool
in 2342 ras cells .
For these studies, 2342 and 2342 pT249a2 cultures were
treated with differentiation-inducing medium supplemented
with concentrations of TPA between 1 nM and 1 p,M . After
48 h, cell extracts were prepared and PKC activity was mea-
sured by in vitro kinase assays . As shown in Fig. 3, 1 and
10 nM TPA did not affect PKC activity levels in either cell
type. The ras cultures maintained a threefold higher level of
PKC activity than the wild-type 2342 cells . After treatment
with 100nM TPA, PKC activity droppedby 54% in the 2342
cultures and by 43% in the 2342 ras cells . Treatment with
1 IAM TPA essentially eliminated PKC activity in both cell
types since the treated 2342 and 2342 pT249a2 cultures re-
tained only 1 and 8% of the PKC activity measured in the
untreated control cultures, respectively. These results dem-
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Figure 3. PKC activity in TPA-treated 2342 and 2342-ras cells.
2342 cells (o) and the differentiation-defective 2342-ras cells (0)
were treated with differentiation-inducing medium supplemented
with concentrations of TPA ranging from 1 nM to 1 tLM . ThePKC
activity in the cell extracts prepared from each culture was mea-
sured as describedin Materials and Methods . Each value represents
the average of four independent determinations, with the exception
of the 500 nM 2342-ras group which was assayed twice . The high
and low values for each group of determinations are indicated by
the range bars .
onstrate that the pool ofPKC protein present in the ras and
the wild-type cells is equally responsive to downregulation
by TPA .
To confirm that the decrease in PKC activity observed af-
ter TPA treatment resulted from proteolysis of the enzyme,
cell extracts were isolated from 2342 and2342 ras cells that
had been treated for 48 h with ITSmedium containing 0nM,
100nM, or 1 P.M TPA . Equal amounts of total protein from
each extract were electrophoresed through an SDS-poly-
acrylamide gel, blotted to nitrocellulose, and then reacted
with a chicken polyclonal antiserum prepared against total
rat brain PKC (49) . As shown in Fig . 4, treatment ofthe cells
with concentrations ofTPA that produced a decrease in PKC
Figure 4. Western blot analysis ofPKC protein in TPA-treated 2342
and 2342-ras cell extracts . Cultures were induced to differentiate
in medium containing 0 nM, 100 nM, or 1 1,M TPA . Cell extracts
were prepared and 66 mg of total protein from each extract were
resolved by SDS-PAGE, transferred to nitrocellulose, and hybrid-
ized with anti-rat brain PKC egg yolk antibodies as described in
Materials and Methods. The control lane contains -125 ng of
purified rat brain PKC.
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activity (Fig . 3) resulted in a corresponding loss of im-
munoreactive protein . 2342 and 2342 ras cultures treated
with 1 PM TPA contained undetectable levels of PKC .
Therefore, based on TPA responsiveness, we conclude that
the PKC protein pool produced by the 23A2 pT249a2 cells
is indistinguishable from the PKC pool found in the wild-
type 23A2 cell line . In addition, these studies provide pre-
liminary support for the hypothesis that the increase in PKC
protein and activity observed in23A2 ras cells is due to alter-
ations in the intracellular pathways regulating PKC synthe-
sis, and not to changes in the pathway responsible for PKC
proteolysis .
DownregulatingPKC Affects the
Morphological Differentiation of2342 Cells,
ButNot the Transcriptional Activation of
Muscle-specific Genes
Since we observed a 50% decrease inPKC activity after the
treatment of 2342 myoblasts with differentiation-inducing
medium, we used the ability of TPA to downregulate PKC
in these cells to address whether the level ofPKC remaining
in 2342 myofibers is essential for the full expression of a
muscle phenotype. 2342 cultures were treated with ITS
medium supplemented with concentrations of TPA from 1
nM to 1 uM . After 48 h, RNA and protein were isolated
from the cultures and examined for expression of several
muscle-specific markers, including muscle creatine kinase
(MCK), troponin I (ThI), and the muscle regulatory factor,
MyoDl . To examine the effect ofTPA on cell fusion, parallel
cultures were treated with TPA-supplemented F12 differen-
tiation-inducing medium and immunochemically stained
with the monoclonal antibody, MF-20 (3), to detect skeletal
myosin heavy chain proteins .
Treatment of 2342 cells with TPA had only a minor effect
on muscle-specific gene expression . All experimental
groups possessed high levels ofMCK activity and had a high
percentage of cells staining positively for skeletal myosin
heavy chains (Table I) . Northern blot analysis of the RNA
isolated from each experimental group demonstrated that the
TPA-treated cultures expressed both ThI andMyoDl mRNAs
(Fig . 5) . These results show that reducing PKC activity does
not significantly affect the molecular mechanisms through
which muscle-specific gene expression is activated or main-
tained in 2342 cells .
The 2342 cultures that were stained immunochemically
for myosin heavy chain protein also were used to assess
whether TPA-treated cells formed multinucleate myofibers
as efficiently as untreated control cells . As shown in Table
I and in Fig. 6, exposing 2342 cells to 100 nM, 500 nM,
or 1 /AM TPA decreased thenumber of myosin-positive mul-
tinucleate cells in the differentiated cultures by up to 80% .
Interestingly, the inhibition of myoblast fusion was apparent
only after treatment of the cultures with concentrations of
TPA that resulted in decreased PKC activity and a loss of im-
munoreactive PKC protein (Figs . 3 and 4), suggesting that
a critical level ofPKC activity is essential for optimal myo-
cyte fusion, but not for maintaining the transcriptional activ-
ity of the muscle-specific gene set (Table I and Fig . 5) .
SinceTPA is a lipophilic compound (reviewed in reference
32), it is possible that the levels of TPA that were used in
these experiments inhibited cell fusion by altering the struc-
813Table L Effects ofTPA on theDifferentiation of
2342 Myoblasts
* Protein extracts isolated from differentiation-induced cultures were assayed
for the muscle-specific isoform of creatine kinase (MCK) as described in
Materials andMethods . The values represent the averages of two independent
experiments andarepresented as creatine kinaseenzyme unitspergram oftotal
protein . Each value has been adjusted for theMCK activity measured in 2342
myoblasts which was 105 enzyme units per gram of protein.
* 2342 cells were induced to differentiate in the presence of increasing con-
centrations of TPA and then stained immunochemically for skeletal myosin
heavy chain protein as described in Materials andMethods . The percentage of
cells expressing the myosin heavy chain protein was calculated by dividing the
numberofnuclei in myosin-positive cells bythe total number ofnucleicounted .
Five randomly chosen microscope fields (3100 nuclei per field) were analyzed
foreach experimental group, and the results from two independent experiments
were averaged to obtain the values presented .
§ Cultures used for the determination ofpercent myosin positive cells also were
used for the determination of percent myofibers by dividing the number of
nuclei contained in cells possessing 32 nuclei by the total number of nuclei
counted per field . Five randomly chosen microscope fields (3100 nuclei per
field) were examined foreach experimental group, and the results from two in-
dependent experiments were averaged to obtain the values presented .
lure of the myocyte plasma membrane . To examine this fur-
ther, 2342 myoblasts were treated with F12 differentiation-
inducing medium containing 1 p,M of the TPA analogue
4a-PMA . Although 4a-PMA has similar lipophilic proper-
ties as TPA, it does not trigger the activation or downregula-
Figure 5. Northern blot analysis of total RNA isolated from TPA-
treated 2342 cells . Cultures were induced to differentiate in
medium supplemented with concentrations ofTPA from 1 nM to
1 jM . 15 Wg of RNA from each culture were electrophoresed
through an agarose/formaldehyde gel, transferred to nitrocellulose,
and probed for MyoDl and Tn1 mRNAs as described in Materials
and Methods . Control lanes contain 15 wg of RNA isolated from
untreated 2342 myoblasts (2342 B) and myofibers (2342 F) .
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tion of PKC (reviewed in reference 32) . In this control ex-
periment, no decrease in cell fusion was detected (Fig . 6),
demonstrating that the ability ofTPA to inhibit myocyte fu-
sion is linked directly to its ability to alter PKC activity in
these cells .
TPA Reatment DoesNot Reverse
theDi fferentiation-defective Phenotype of
2342 ras Cells
Our examination ofthe role ofPKC activity in the differenti-
ation of wild-type 2342 myoblasts suggests that a reduction
inPKC activity certainly is not deleterious to2342 cells and
that a modest reduction may be essential for the proper exe-
cution of the skeletal muscle differentiation program . There-
fore, since differentiation-defective 2342 ras cells possess
elevated levels ofPKC activity, we decided to test whether
myogenesis could be restored in these cultures by lowering
the levels ofPKC . 2342 pT249a2 cells were treated with F12
differentiation-inducing medium supplemented with concen-
trations ofTPA from 1 nM to 1 AM . After 4 d, the cultures
were fixed, stained immunochemically with the MF-20
monoclonal antibody, and observed for morphological dif-
ferentiation . In all cases, neither myofiber formation nor
myosin heavy chain gene expression was detected (data not
shown) . RNA was isolated from parallel cultures and North-
ern hybridizations performed to detect expression ofmuscle-
specific genes . As expected from the absence of morphologi-
cal differentiation, the TPA-treated ras cells did not express
TnI or MyoDl mRNAs, but did continue to express
significant levels of mRNA transcribed from the transfected
H-ras gene (Fig . 7 A) . We conclude from these studies that
continued high levels of PKC activity are not required to
maintain the differentiation-defective phenotype of this es-
tablished ras cell line .
We also examined whether TPA treatment affected the
level of ras protein in the cells . 2342 and 2342 pT249a2 cul-
tures were treated for 48 h with ITS medium containing 500
nM TPA and total ras protein was immunoprecipitated from
31S-labeled cell extracts using the pan-reactive ras mono-
clonal antibody, Y13-259 (20) . The results of this analysis
demonstrate that both 2342 and 2342 ras cells exhibit a mea-
surable decrease in ras protein after treatment with TPA
(Fig . 7 B) . However, as was indicated by the Northern analy-
sis (Fig. 7 A), TPA-treated ras cells continue to express acti-
vated ras p21 and possess at least twofold more ras protein
than TPA-treated wild-type cells (Fig . 7 B) . Since the 2342
ras cultures do not differentiate in the presence of TPA, ei-
ther the amount of activated ras p21 remaining in the ras
cells is sufficient to inhibit differentiation or, alternatively,
high levels of ras p21 (like high levels of PKC activity) are
not required to maintain the differentiation-defective pheno-
type of the 2342 pT249a2 cells .
Initiation of the Differentiation-defective Phenotype of
2342 ras Cells RequiresPKC
Although it appears that an elevated level ofPKC activity is
not required to maintain the nonmyogenic phenotype of
2342 ras cells, activated ras p21 may rely on PKC to initiate
its negative effects on skeletal myogenesis . To examine this
possibility stable transfection experiments were performed .
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Concentration
of TPA
nM
MCK activity*
Myogenic marker
Percent myosin
positive cells*
Percent
myofibers§
0 3,020 83 76
1 3,205 85 77
10 2,345 75 68
100 1,505 76 47
500 2,075 67 16
1,000 1,865 67 16Figure 6. Inhibition of myoblast fusion byTPA . 23A2 myoblasts were induced to differentiate in medium supplemented with concentrations
of TPA from 1 nM to 1 AM . The differentiated cultures were fixed, immunochemically stained to detect myosin heavy chain protein (see
Materials and Methods for details), and photographed under bright light conditions . A shows the level of background staining obtained
with undifferentiated 23A2 myoblast cultures . B-E show the morphology of 23A2 myofibers that have differentiated in the presence of 0
nM (B), 10 nM (C), 100 nM (D), and 1 AM TPA (E) . F shows 23A2 cells that were induced to differentiate in the presence of 1 AM
4a-PMA, a non-functional analogue of TPA . Bar, 100 Am .
Wild-type 23A2 myoblasts were maintained in normal
growth medium or in growth medium supplemented with
500 nM TPA . TPA-treated and untreated 23A2 myoblasts
were cotransfected with a single calcium phosphate precipi-
tate containing either a selectable marker (pKOneo) and the
oncogenic form of thehuman H-ras gene (pT24) or pKOneo
and the human H-ras proto-oncogene (p3B) . Each trans-
fected culture then was divided into experimental groups that
were maintained in selective medium supplemented with
TPA for various lengths oftime (Fig . 8) . After colonies had
formed (ti15 d), the cultures were treated with F12 differ-
entiation-inducing medium (supplemented with TPA where
indicated), fixed, stained with Giemsa, and analyzed for the
percentage of myogenic colonies (Fig . 8) . For the control
groups transfected with the H-ras proto-oncogene (groups A
and B), 86% of the untreated colonies and 75% of the TPA-
treated colonies were differentiation competent. We attribute
the modest decrease in myogenesis observed for group B to
the difficulty of scoring myogenesis in cultures where myo-
cyte fusion is reduced by TPA (Fig . 6) . For the parallel ex-
perimental groups transfected with the H-ras oncogene
(GroupsC and F), only 11% of the colonies in the untreated
cultures were competent for differentiation, while 54% of
the colonies arising from the TPA-treated cultures contained
differentiated cells . The fivefold increase in the myogenic
competence of ras-transfected cells that were pretreated with
TPA suggests that the downregulation of PKC by TPA pre-
vents activated ras p21 from exerting its full negative effects
on skeletal myogenesis .
We next compared the results of Groups C and F with the
results obtained from additional experimental groups in
which TPA was added or removed from the 23A2 cultures
at various times after transfection with the H-ras oncogene .
Vaidya et al . Role ofPKC in Skeletal Muscle Development
As shown in Fig. 8, a two-, three-, and fivefold increase in
the percentage of differentiated colonies was obtained when
the cells were treated with TPA on days 10, 4, and -1,
respectively (compare Group C with Groups D, E, and F),
demonstrating that early treatment with TPA enhances the
frequency of myogenic colonies . Similarly, the longer TPA
remained on the cells after transfection, the less effective ras
p21 was in inhibiting myogenesis . Cultures maintained in
TPA for 4, 10, or 19 d produced 16, 35, and 54% differen-
tiated colonies, respectively (compare Groups H, G, and F) .
The results presented in Fig . 8 were compiled from three
independent transfection experiments . For Experiment 3,
RNA was isolated from each group and Northern blot
hybridizations performed to assess the levels ofMyoDl, TnI,
and ras mRNAs in each culture . As expected, the levels of
MyoDl and ThI gene expression determined for each group
reflected the percentage of colonies that differentiated into
skeletal myofibers (Fig. 9) . As previously described for the
23A2 pT249a2 cell line, all groups treated with TPA ex-
hibited reduced levels of activated ras gene expression (Fig .
9) and it is possible that this contributes to the increase in
myogenic competence that is observed . On the other hand,
it is not known how much activated ras p21 is required to
inhibit 23A2 myogenesis, although the high frequency of
non-myogenic colonies arising from a neo/ras cotransfection
(Group C) suggests that colonies expressing even minimal
levels ofras are scored as non-myogenic by our assay. There-
fore, we conclude that ras p21 relies on PKC activity to initi-
ate the intracellular changes responsible for inhibiting myo-
genesis . However, based on our results with the 23A2
pT249a2 cell line (Fig . 6), a continued high level ofPKC ac-
tivity is not required to maintain the differentiation-defective
phenotype of ras myoblasts .
815Discussion
In this study, we have examined thechanges in protein kinase
C activity that are associated with the terminal differentia-
tion of 23A2 myoblasts and the differentiation-defective
phenotype of 23A2 ras cells . Our interest in PKC as amajor
component of the signal transduction pathway(s) that regu-
lates skeletal myogenesis comes from two lines of evidence .
First, experiments with primary avian myoblasts have dem-
onstrated that exogenous activators of PKC, such as phorbol
estertumorpromoters, adversely affect several developmen-
tal events associated with skeletal myogenesis, including the
fusion of cells and the expression of muscle-specific genes
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Figure 7 . Northern blot analysis of total
RNA isolated from TPAtreated 23A2-
ras cells . Cultures were fed differen-
tiation-inducing medium supplemented
with concentrations ofTPA from 1 nM
to 1 t.M . 15 jig of total RNAwere elec-
trophoresed through an agarose/formal-
dehyde gel, transferred to nitrocellulose,
andprobed for MyoDl andThl mRNAs
as described in Materials and Methods .
The filter was subsequently stripped of
the previous probes by washing in 0.lx
SSC containing 0.1% SDS for30 min at
90-100°C with onechange ofwash solu-
tion and then reprobed forthe expression
ofthe transfected H-ras oncogene (ras).
Control lanes contain 15 Fig of total
RNA from 23A2 myoblasts (23A2 B),
23A2 myofibers (23A2 F), proliferating
23A2-ras cells (ras B), and differentia-
tion-induced 23A2-ras cells (ras F) . (B)
Immunoprecipitation of total ras p21
from 23A2 myoblasts (23A2) and the
differentiation-defective 23A2 pT249a2
cells (23A2-ras) . Cells were metaboli-
cally labeled with [3'S]methionine in
the presence (+) or absence (-) of 500
nM TPA. ras p21 was immunoprecipi-
tatedfromlabeled cell extracts using the
Y13-259 antibody (20) and electropho-
retically resolved on a denaturing poly-
acrylamide gel . Quantitation of the ras
p21 in each sample was achieved by ex-
cising the relevant portion of each lane
and counting in a scintillation counter.
Background counts obtained from paral-
lel lanes precipitated without the Y13-
259 antibody (not shown) were subtracted
from each value before expression as
cpm/mgprotein.The values reported for
each sample represent the average of
three independent determinations .
(8, 41) . Second, several laboratories have found that expres-
sion of activated ras p21 in mammalian cells leads to a con-
stitutive increase in intracellular diacylglycerol (18, 24, 28,
39, 50) whichserves as an endogenous activator ofPKC (re-
viewed in references 34, 35) . Theseobservations support the
hypothesis that PKC plays an important role in controlling
normal skeletal myogenesis and that changes in PKC activity
may be instrumental in the ras-induced inhibition of skeletal
muscle differentiation .
The differentiation of wild-type 23A2 myoblasts is asso-
ciated with a 50% reduction in PKC activity, suggesting that
a decrease in PKC levels may be critical to achieving and
maintaining aterminally differentiatedphenotype . Prolonged
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treatment of differentiation-induced 23A2 cells withTPA re-
sults in a further reduction ofPKC activity andalthough this
treatmenthasno effect on biochemical differentiation, the fu-
sion of the cells inhibited . This result indicates that a certain
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Figure 8 . TPA treatment of 23A2 cells blocks the inhibition of myogenesis by activated ras p21. 23A2 cells were treated with 500 nM
TPA for various times before or after transfection with pKOneo and either the H-ras proto-oncogene (Control) or the H-ras oncogene
(ras) . After selection of G418-resistant colonies, the cultures were induced to differentiate andthen analyzed for the number of myogenic
colonies as described in Materials and Methods. The results of the colony counts for three independent transfection experiments are pre-
sented individually (Exp . 1, Exp. 2, andExp. 3) and as an average for each experimental group. (°) The number of myogenic colonies ex-
pressed as a percentage of the total number of colonies analyzed . (b) The average of the percentages obtained from Exps . 1, 2, and 3 .
level of PKC activity is required for proper morphological
differentiation . In this regard, David et al . (10) have exam-
ined the biochemical events associated with the differentia-
tion of primary chick myoblasts and have shown that PKC
Figure 9 . Northern blot analysis of total RNA
isolated from Groups A-H of Exp . 3 in Fig . 8 .
15 Rg ofRNA from each experimental group
wereelectrophoresed through an agarose/form-
aldehyde gel, transferred to nitrocellulose, and
probed for MyoD1 and Tnl mRNAs as de-
scribed in Materials and Methods . The filter
then was stripped as described in Fig. 7and re-
probed for expression of the transfected H-ras
oncogene (ras) . Control lanes contain 15 lag of
total RNA from 23A2 myofibers (23A2 MF),
differentiation-induced 23A2 pT249a2 cells
treated (23A2-ras + TPA) or not treated (23A2-
ras) with 500 nM TPA, and C3H10T1/2 fibro-
blasts (C3HIOT1/2) . The lower panel shows
the ethidium bromide-stained gel before trans-
fer of the RNA to nitrocellulose .
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216 274 ' 250activity stimulates membrane events, such as the influx of ex-
tracellular calcium, that are necessary prerequisites for cell
fusion.
Differentiation-defective 23A2 ras cells possess elevated
levels of PKC activity as judged by three separate measure-
ments: in vitro kinase assays (Fig. 1), THE-CAT assays (Fig.
2), and Western analyses (Fig. 4). Prolonged treatment of
23A2 pT249a2 cellswith TPA effectively reduced PKC activ-
ity to undetectable levels, but did not restore myogenic com-
petence to the cultures (Fig. 7 A). In contrast, when 23A2
cells were pretreated with TPA and then transfected with
the ras oncogene, normal biochemical differentiation was
achieved in a high percentage of the transfected colonies
(Figs. 8 and 9, Group F). This observation, combined with
our analysis of the 23A2 pT249a2 cell line, suggests that ras
relies on PKC to initiate the inhibition of myogenesis, but
that a continued high level of PKC expression is not required
for the block in myogenesis to be maintained.
Examination of the levels of ras protein in wild-type and
ras-transfected 23A2 cellsreveals a decrease in ras p21 after
treatment with TPA (Fig. 7 B). The decrease observed is
similar for both cell types and the 23A2 pT249a2 cells retain
at least twofold more ras p21 than the wild-type cells. Since
the Y13-259 ras antibody used for this experiment does not
distinguish between the endogenous mouse and transfected
human ras p21 species, it is impossible to assess the level
of activated ras p21 in the TPA-treated 23A2 pT249a2 cells.
However, it is apparent from the Northern analyses that
significant levels of the activated human H-rasmRNA persist
in ras-transfected cells that are exposed to TPA (Figs. 7 A
and 9) . The contribution of a modest reduction in ras p21
expression to the results reported here is not clear. The ina-
bility of TPA treatment to restore differentiation in 23A2
pT249a2 cells would suggest that the level of activated ras
p21 remaining in these cells is sufficientto inhibit differenti-
ation or, alternatively, that ras p21 (like PKC activity) is not
required to maintain the non-myogenic phenotype of 23A2
ras cells. We favor the former possibility since Gossett et al.
(21) have demonstrated that sustained expression of an in-
ducible N-ras oncogene is absolutely essential for the main-
tenance ofthe ras-induced inhibition of C2 skeletal myogen-
esis. Similarly, the partial suppression of ras p21 expression
by TPA cannot explain the results of the transfection experi-
ments reported in Fig. 8 for the following reasons. First, our
experience with 23A2 cells has demonstrated that the
efficiency of cotransfection in these cultures is, at best,
80-90% (Vaidya, T., and E. Taparowsky, unpublished re-
sults) . Therefore, it is likely that the 11% differentiation-
competent colonies observed for Group C (Fig. 8) represent
cells that are expressing only the neomycin resistance gene
and the remaining differentiation-defective colonies (89%)
represent cells that have been cotransfected with neo and ras
and, thus, express various amounts of activated ras protein.
Second, Northern analysis of RNA isolated from pooled
populations indicates that the levelofactivated H-rasmRNA
is decreased similarly in all TPA-treated groups (compare
Fig. 9, Groups D-H), yet the percentage of myogenic colo-
nies varies from 23 % in Group D to 57% in Group F. These
observations support the conclusion that the activated ras
protein relies on PKC activity to initiate its full negative
effects on skeletal muscle differentiation. In this regard,
studies exploring the mitogenic effects of ras p21 in mam-
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malian fibroblasts have demonstrated that the metabolic con-
sequences of ras activation can be separated into PKC-
dependent and PKC-independent events (6, 31) . Our results
suggest that the effects of activated ras p21 on 23A2 myo-
blasts show a similar pattern with short-term PKC-dependent
and long-term PKC-independent events collaborating to in-
hibit skeletal muscle differentiation .
In mammalian fibroblasts, activated ras gene expression
leads to increased diacylglycerol production, which results
in the activation and subsequentdownregulation ofPKC (24,
50) . In previous studies, we have demonstrated that ras-
transfected C3H10T1/2 cells, the fibroblast cell line from
which the 23A2 myogenic cell line was derived originally
(26), show a 40% downregulation of PKC activity and pro-
tein (49). Although we have preliminary data indicating that
23A2 ras cellspossess elevated levels of diacylglycerol com-
pared to control cells (Vaidya, T., and E. Tàparowsky, un-
published results), our present studies have shown that 23A2
ras cells possess at least 10 times more PKC protein (Fig.
4) and two- to threefold more PKC activity (Figs. 1 and 3)
than wild-type myofibers. Why PKC accumulates to a high
level in 23A2 ras cells is not clear. One possibility is that ras
induces expression of additional isozymes of PKC that dis-
play partial or complete resistance to downregulation.
Cooper et al . (9) have demonstrated that BC3H1 myocytes
express a type H PKC isozyme that displays a preference for
phosphorylating vinculin, not histone, and is refractile to
downregulation by TPA. We have addressed whether a simi-
lar isozyme switch has occurred in 23A2 ms cells using in
vitro kinase assays and Western blot analyses with a poly-
clonal antiserum raised against all of the major PKC iso-
zymes to measure how the PKC pool in 23A2 ras cells
responds to treatment with TPA. Our results indicate that the
pool ofPKC produced by the 23A2 ras cellsand the pool pro-
duced by wild-type 23A2 cells are equally responsive to
phorbol ester downregulation (Figs. 3 and 4). This suggests
that 23A2 ras cells accumulate PKC because of an increased
rate of PKC synthesis, and in vivo labeling experiments cur-
rently are beingperformed to address this possibility. In ad-
dition, we are intrigued by the observation that the 23A2 ras
cells contain substantially more PKC protein than predicted
from the kinase activity values (compare Figs. 3 and 4). In
preliminary studies, we have found that the partial purifica-
tion of PKC from 23A2 ras cell extracts dramatically in-
creases the kinase activity of the protein (Weyman, C., and
C. Ashendel, unpublished results). This suggests that 23A2
ras cellsmay produce an unknown inhibitor ofPKC activity.
Whether this inhibitor influences directly the accumulation
of PKC in the ras cells remains to be explored.
We have used the 23A2 myogenic cell line to address fun-
damental questions concerning cellular growth control .
Defining the molecular mechanisms through which an acti-
vated ras oncogene transforms cells and subverts the proper
control of cellular differentiation is an intriguing problem.
Our studies demonstrate that the signal transduction path-
ways used by ras p21 to inhibit 23A2 skeletal myogenesis
rely on PKC activity and have as a nuclear target the down-
regulation of the MyoD1 regulatory gene. Interestingly,
growth factor-mediated signal transduction remains the cat-
alyst in initiating myogenic differentiation, since wild-type
cells that express high levels of MyoDl, or ras cells en-
gineered to express a MyoD] eDNA, do not differentiate in
818the presence of serum, FGF, or TGF-Q (26, 30, 46) . In addi-
tion, our studies indicate that the growth factors important
to skeletal myogenesis may operate independently of PKC
activity, since severely reducing PKC levels in proliferating
23A2 myoblasts does not elicit a precocious differentiation
response. Undoubtedly, an important question for future
studies will be to address how the myogenic regulatory fac-
tors, such as MyoDl, are modified in cells exposed to these
various agents, since it is apparent that subtle changes in the
state of these proteins are essential to the proper initiation
and maintenance of the myogenic lineage.
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